NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NEUROCRINE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$136.98+1.27 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $14.27B
- P/E (TTM)
- 20.1
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
98.2%−0.9 pts over 5 years
Operating margin
21.6%+6.1 pts over 5 years
Net margin
16.7%−22.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +21.4% | +24.3% | +22.3% | +64.5% | |
| Gross profit | +21.0% | +24.2% | +22.1% | +64.2% | |
| Operating income | +8.5% | +35.5% | +30.6% | – | |
| Net income | +40.2% | +45.8% | +3.3% | – | |
| EPS, diluted | +41.9% | +44.1% | +2.3% | – | |
| Free cash flow | +34.4% | +32.4% | +28.0% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -38.2% | 46.2% | 16.4% | |
| Return on assets | -33.6% | 26.8% | 11.5% | |
| Current ratio | 10.21 | 5.45 | 3.39 | |
| Interest coverage | – | 5.0× | – | |
| Inventory turnover | – | 0.4× | 0.8× | |
| Capex to revenue | 27.4% | 1.0% | 1.2% | |
| Diluted shares | 87M | 98M | 103M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Neurocrine Biosciences generated $2.36B from operations and spent $608.10M on capital expenditure, dividends and share buybacks. 23% of that went back into the business.
Generated
$2.36B
Used
$608.10M
Capital expenditure$140.40M23%Dividends$00%Share buybacks$467.70M77%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin16.7%
×Asset turnover0.69×
×Equity multiplier1.43×
=Return on equity, FY202516.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 16.7% | 0.69× | 1.43× | 16.4% |
| FY2024 | 14.5% | 0.68× | 1.45× | 14.2% |
| FY2023 | 13.2% | 0.67× | 1.43× | 12.7% |
| FY2022 | 10.4% | 0.67× | 1.44× | 10.0% |
| FY2021 | 7.9% | 0.60× | 1.52× | 7.2% |
| FY2020 | 38.9% | 0.69× | 1.72× | 46.2% |
| FY2019 | 4.7% | 0.69× | 2.06× | 6.6% |
| FY2018 | 4.7% | 0.50× | 2.12× | 4.9% |
| FY2017 | -88.2% | 0.27× | 1.72× | -41.5% |
| FY2016 | -940.6% | 0.04× | 1.14× | -38.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$478.60M
- Cash generatingOperating cash flow above zero$782.70M
- Return on assets improvedROA up on the prior year10.5% → 12.9%
- Earnings backed by cashOperating cash flow above net income$782.70M vs $478.60M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.40 → 3.39
- No dilutionShare count did not rise104M → 103M
- Gross margin improvedGross margin up on the prior year98.56% → 98.18%
- More efficientAsset turnover rose0.72 → 0.77